BYSI BeyondSpring Inc.

17.77
+0.05  (+0%)
Previous Close 17.72
Open 17.77
Price To Book 20.67
Market Cap 411897254
Shares 23,174,797
Volume 220
Short Ratio
Av. Daily Volume 2,651

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint of non-inferiority vs Neulasta. NDA filing due 2H 2019.
Plinabulin (Trial 105)
Chemotherapy-induced neutropenia (CIN)
Phase 3 interim data due 1H 2019.
Plinabulin (Trial 103)
Non small cell lung cancer - refractory
Phase 2 top-line positive data released October 23, 2018, with additional data presented at SITC March 2019.
Plinabulin + TAC (Trial 106)
Chemotherapy-induced neutropenia (CIN)
Phase 1/2 initiation announced October 4, 2018.
Plinabulin + Opdivo +Yervoy
Small-cell lung cancer (SCLC)

Latest News

  1. BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
  2. BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference
  3. BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
  4. New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia
  5. How to spot risky biotech companies and six to avoid now
  6. BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin
  7. United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring’s Lead Asset Plinabulin with Protection to 2036
  8. BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
  9. Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF
  10. Can The Uptrend Continue for BeyondSpring (BYSI)?
  11. Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia
  12. Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  13. Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®
  14. Who Really Owns BeyondSpring Inc (NASDAQ:BYSI)?